Lymphoma: long-term ZUMA-5 follow-up

Five-year ZUMA-5 follow-up provides long-term observations in indolent lymphoma. Applicability first depends on the pathological subtype.

Clinical study follow-up

On this page

1.Population and background
2.What the evidence shows
3.Conclusions that cannot be drawn
4.Questions to ask your doctor

Population and background

Relapsed or refractory indolent non-Hodgkin lymphoma, including follicular and marginal zone lymphomas.

What the evidence shows

ZUMA-5 enrolled 159 patients with relapsed or refractory indolent non-Hodgkin lymphoma. The 2025 five-year analysis reported an overall response rate of 90% and complete response rate of 75%. These are study population results; read follow-up, survival and adverse event information alongside them.

Conclusions that cannot be drawn

ZUMA-5 results cannot serve as a universal efficacy estimate for diffuse large B-cell lymphoma. They do not establish that all Chinese patients obtain the same outcomes or payment coverage.

Questions to ask your doctor

Was my lymphoma subtype included in ZUMA-5? Which indication applies to the proposed CAR-T product, and how will adverse reactions be monitored and long-term follow-up arranged?

Related technologies and evidence

Lymphoma · Leukaemia · Gastric cancer

Distinguish approval from research for each product

CAR-T cell therapy

T cells are modified to recognise tumour targets. Approved blood cancer products and solid tumour studies have different eligibility criteria.

Sources (3)

T-cell Transfer Therapy ↗ (opens in a new window)National Cancer Institute
CT041-ST-01 randomised open-label phase II trial ↗ (opens in a new window)The Lancet / PubMed · 2025
Marketing approval information for ciltacabtagene autoleucel injection ↗ (opens in a new window)National Medical Products Administration · 2025-02-19

View details

Related cancer types and preparation for care

Lymphoma →Record preparation and the care process →

Sources and scope of interpretation

The following sources support the disease information or explanations of evidence on this page. Access and actual patient acceptance requirements must be checked separately for each region. The information checking date does not indicate review by an external medical expert.

Five-Year Follow-Up Analysis of ZUMA-5 ↗ (opens in a new window)Journal of Clinical Oncology / PubMed · 2025

Tell us what help you need

Ask about the costs and arrangements for cancer care. SinoCareHub helps organise records, contact hospitals and follow up on arrangements. The receiving hospital and doctors determine the diagnosis and treatment plan.

Describe your needs in the initial consultation. The team will help organise medical records in subsequent communication.